- Home
- MRSN
as of 12-05-2025 3:02pm EST
$27.80
+$0.33
+1.20%
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Chart Type:
Time Range:
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 138.8M | IPO Year: | 2017 |
| Target Price: | $30.38 | AVG Volume (30 days): | 237.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.21 - $70.73 | Next Earning Date: | 11-14-2025 |
| Revenue: | $33,180,000 | Revenue Growth: | -4.76% |
| Revenue Growth (this year): | -41.32% | Revenue Growth (next year): | -12.07% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
Bala Mohan
Sell
SVP, Chief Development Officer
MRSN Oct 27, 2025
Avg Cost/Share
$9.90
Shares
77
Total Value
$762.30
Owned After
2,922
SEC Form 4
Huber Martin H. Jr.
Sell
President, CEO
MRSN Sep 12, 2025
Avg Cost/Share
$7.31
Shares
2,012
Total Value
$14,707.72
Owned After
9,572
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bala Mohan | MRSN | SVP, Chief Development Officer | Oct 27, 2025 | Sell | $9.90 | 77 | $762.30 | 2,922 | |
| Huber Martin H. Jr. | MRSN | President, CEO | Sep 12, 2025 | Sell | $7.31 | 2,012 | $14,707.72 | 9,572 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
MT Newswires
BioNTech Says Minimum Condition Met in CureVac Exchange Offer
📊
AI Sentiment
Positive
6/10
MT Newswires
North American Niobium And Critical Minerals Says Completed Phase 1 Fall Prospecting Program
➖
AI Sentiment
Neutral
4/10
Investor's Business Daily
Stock Market Today: Indexes Mixed After Surprise Jobs Data; Software Name Tumbles (Live Coverage)
GlobeNewswire
The Bank of Glen Burnie Names Todd Capitani to its Leadership Team as Chief Financial Officer
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Sagent Launches Bludigo®, an Indigo Carmine Injection, Through New Partnership with Provepharm
📈
AI Sentiment
Highly Positive
8/10
Compare MRSN vs Leading Stocks
See how MRSN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.